UIC-2015-039 – Development of a Peptide Nanoparticle Inhibitor of CCR3-mediated Eosinophilic Inflammation in Asthma and Allergy

Approximately 24 million Americans suffer from asthma, with the prevalence rising by 2% annually. More than 60% of allergic asthma is eosinophilic in nature. These symptoms have been treated using bronchodilators, corticosteroids or their combinations. It is likely that no one approach is going to successfully treat all the various asthma phenotypes. Current biologics include the use cytokines, Anti-IL-5/IL-5R and their combinations to target eosinophils and other inflammatory cells. CCR3 is a validated eosinophilic asthma target with a number of small molecule inhibitors in various stages of clinical development. The current technology uses R321- a novel biased antagonist that binds to the CCR3 receptor at the same time as the eotaxin ligands to form nanoparticles that protect peptide from proteolytic degradation and promoting its removal from the eosinophil surface and blocking the recruitment of multiple CCR3 ligands. Nelson Grihalde grihalde@otm.uic.edu 312-996-4129

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More